Premium
High‐Dose Intravenous Gammaglobulin Therapy for Neonatal Immune Haemolytic Jaundice due to Blood Group Incompatibility
Author(s) -
SATO K.,
HARA T.,
KONDO T.,
IWAO H.,
HONDA S.,
UEDA K.
Publication year - 1991
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1991.tb11828.x
Subject(s) - medicine , gamma globulin , jaundice , abo blood group system , refractory (planetary science) , adverse effect , gastroenterology , immunology , pediatrics , antibody , physics , astrobiology
. Three newborn infants who developed hyperbilirubinemia due to blood group incompatibility were treated with high‐dose gammaglobulin. Hyperbilirubinemia was caused by Rhesus (Rh) incompatibility (anti‐E + anti‐c) in Infant 1 and ABO incompatibility (anti‐B) in Infants 2 and 3. Hyperbilirubinemia was refractory to conventional phototherapy but responded well to intravenous gammaglobulin (IVGC) at dose of 1 g/kg in all infants. No adverse effects were observed. These findings suggest that high‐dose IVGG may be useful in the treatment of hyperbilirubinemia due to isoimmune baemolytic disease resistant to phototherapy.